Heron Therapeutics, Inc. (NASDAQ:HRTX) was the target of a large decrease in short interest in the month of August. As of August 15th, there was short interest totalling 12,723,565 shares, a decrease of 8.6% from the July 31st total of 13,920,842 shares. Based on an average daily volume of 505,331 shares, the days-to-cover ratio is presently 25.2 days. Currently, 23.9% of the company’s shares are sold short.

A number of research firms have recently weighed in on HRTX. BidaskClub cut Heron Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, August 18th. Cantor Fitzgerald set a $31.00 price target on Heron Therapeutics and gave the stock a “buy” rating in a report on Friday, August 18th. Noble Financial reiterated a “buy” rating on shares of Heron Therapeutics in a report on Thursday, August 10th. Jefferies Group LLC reiterated a “buy” rating on shares of Heron Therapeutics in a report on Wednesday, August 16th. Finally, Cowen and Company set a $40.00 price target on Heron Therapeutics and gave the stock a “buy” rating in a report on Thursday, August 3rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eleven have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $31.00.

Large investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC purchased a new stake in Heron Therapeutics during the second quarter worth $78,134,000. Tang Capital Management LLC increased its stake in Heron Therapeutics by 39.7% in the first quarter. Tang Capital Management LLC now owns 8,654,914 shares of the biotechnology company’s stock worth $129,824,000 after buying an additional 2,457,716 shares during the period. FMR LLC increased its stake in Heron Therapeutics by 36.7% in the first quarter. FMR LLC now owns 8,030,880 shares of the biotechnology company’s stock worth $120,464,000 after buying an additional 2,158,041 shares during the period. Citadel Advisors LLC increased its stake in Heron Therapeutics by 529.5% in the first quarter. Citadel Advisors LLC now owns 1,283,679 shares of the biotechnology company’s stock worth $19,255,000 after buying an additional 1,079,746 shares during the period. Finally, Broadfin Capital LLC increased its stake in Heron Therapeutics by 26.9% in the first quarter. Broadfin Capital LLC now owns 4,947,403 shares of the biotechnology company’s stock worth $74,211,000 after buying an additional 1,047,816 shares during the period.

Heron Therapeutics (NASDAQ:HRTX) opened at 16.50 on Friday. The company’s 50-day moving average price is $16.13 and its 200-day moving average price is $14.85. Heron Therapeutics has a one year low of $12.21 and a one year high of $20.85.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.80) EPS for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.10. The business had revenue of $8.51 million during the quarter, compared to the consensus estimate of $4.53 million. Equities analysts forecast that Heron Therapeutics will post ($3.51) EPS for the current year.

WARNING: This news story was first posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.watchlistnews.com/heron-therapeutics-inc-hrtx-short-interest-update/1535259.html.

About Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.